BioSpace News Archive

North America Is Expected To Witness 45% Of Breast Cancer Diagnostics Market Share Due To Well-Established Diagnostic Infrastructure And Technological Advancements

Wilmington, Delaware, United States, Transparency Market Research Inc. - Cancer profiling is an alternative to all traditional approaches to cancer treatment. It uses a focused personalized approach to a treatment that specifically targets an individual patient’s tumor.

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 8:45 a.m. ET.

Black Americans (63%) are significantly more likely than Hispanic Americans (49%) and White Americans (47%) to have no awareness of celiac disease and/or gluten-sensitivity, suggesting potential health inequities in both diagnosis and treatment, according to a nationwide benchmark survey conducted by The Harris Poll on behalf of Beyond Celiac, the leading catalyst for a celiac disease cure.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Drug delivery devices are specialized tools used for the delivery of a drug or therapeutic agent through a specific route of administration.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Immunoglobulins are highly purified, sterile-specific medical therapy solutions containing gamma globulin G (IgG) in a concentration of 95% or more

After successfully completing in vitro and in vivo (mice) experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer cells and significantly increases survival rates, Oncolyze now has its sights set on advancing OM-301 into clinical trials.

The global pharmaceutical drug delivery market is expected to reach USD 2.21 Billion by 2027, according to a new report by Reports and Data.

The global tissue diagnostic market is expected to reach USD 5.02 Billion by 2027, according to a new report by Reports and Data.

Jacobio Pharma (1167.HK), an innovative novel drug developer focused on undruggable targets, released interim 2022 results, new business updates and expected milestones.